domingo, 18 de febrero de 2018

Delftia tsuruhatensis, an Emergent Opportunistic Healthcare-Associated Pathogen - Volume 24, Number 3—March 2018 - Emerging Infectious Disease journal - CDC

Delftia tsuruhatensis, an Emergent Opportunistic Healthcare-Associated Pathogen - Volume 24, Number 3—March 2018 - Emerging Infectious Disease journal - CDC

Volume 24, Number 3—March 2018

Research Letter

Delftia tsuruhatensis, an Emergent Opportunistic Healthcare-Associated Pathogen

Alexandre Ranc1, Grégory Dubourg1, Pierre Edouard Fournier, Didier Raoult, and Florence Fenollar1Comments to Author 
Author affiliations: MEPHI, UMR, IRD, Aix-Marseille Université, Institut Hospitalo-Universitaire Méditerranée Infection, Marseille, France (A. Ranc, G. Dubourg, D. Raoult)VITROME, Institut Hospitalo-Universitaire Méditerranée Infection, Marseille (P.E. Fournier, F. Fenollar)


Delftia tsuruhatensis, which was first isolated in environmental samples, was rarely associated with human infections. We report on pneumonia caused by D. tsuruhatensis in an infant who underwent cardiac surgery. Retrospective analyses detected 9 other isolates from 8 patients. D. tsuruhatensis is an emergent pathogen, at least for immunocompromised patients.
Delftia tsuruhatensis, a member of the Comamonadaceae family, was first isolated from sludge in Japan in 2003 (1). Mainly studied for environmental purposes (2,3), D. tsuruhatensis has rarely been identified in humans (4,5). We present a case report of a respiratory infection caused by D. tsuruhatensis in a premature infant.
A female infant, born premature at 36 weeks’ gestation, had a cardiac congenital pathology for which resection of the ductus arteriosus and pacemaker placement were performed at 4 months of age. During the immediate follow-up period, she developed acute renal failure, which was treated by peritoneal dialysis. Her undernutrition status required enteral and parenteral nutrition. Laboratory tests showed slight leukocytosis, with elevated neutrophils at 9.2 G/L (reference range 1.4–8.5 G/L), monocytosis at 2.1 G/L (reference 0.2–2.0 G/L), and an elevated C-reactive protein at 15.1 mg/L (reference 0–5 mg/L). Two days after surgery, the infant developed pneumonia associated with ventilator-associated hypoxia, which prompted bronchial aspiration sampling that was sent to the clinical microbiology laboratory for analysis, which was performed as previously described (6). Colonies grew after 24 hours’ incubation on both Polyvitex and Columbia media (bioMérieux, Craponne, France) in pure culture at 107 CFU/mL. We correctly identified the isolate using matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry (Microflex, Bruker, Leipzig, Germany), as previously described (7). We maintain a custom MALDI-TOF mass spectrometry database that is updated regularly and enabled identification of the colony as D. tsuruhatensis, with an identification score of 2.082. We confirmed identification of the strain using 16S rDNA amplification coupled to sequencing, as previously reported (8). We obtained an amplicon of 1,296 bp and identified it as D. tsuruhatensiswith a similarity of 99.70% with GenBank sequence no. KC572558. Because the strain was negative for d-mannitol assimilation as highlighted using API NE (bioMérieux), we excluded possible misidentification with D. lacustris.
We tested for antimicrobial drug susceptibility according to EUCAST 2017 recommendations (9) using the Etest gradient method. We categorized the strain as resistant to amoxicillin (MIC >256 mg/L) and amoxicillin/clavulanate (MIC >256 mg/L) but susceptible to ceftriaxone (MIC 0.5 mg/L), ertapenem (MIC 0.5 mg/L), imipenem (MIC 0.5 mg/L), and ofloxacin (MIC 0.047 mg/L). We administered ceftazidime to the patient for 10 days. Further collected samples were negative on culture.
One month later, the infant became febrile (temperature 39°C); a chest radiograph revealed pneumonia, and testing showed a still-elevated C-reactive protein (15 mg/L). A new bronchial aspiration was obtained and inoculated, as described previously. Twenty-four hours after incubation, we observed 2 isolates, each growing 105 CFU/mL, and analyzed them by MALDI-TOF mass spectrometry. One isolate was identified as D. acidovorans (score 2.207). Faced with the discrepancy with the previous results, we performed 16S rRNA PCR coupled with sequencing, as previously reported, enabling the identification of D. tsuruhatensis with a sequence identity of 99.70% to GenBank sequence no. KC572558. We identified the other isolate as Neisseria macacae, with a score of 2.033.
We initiated therapy with imipenem, vancomycin, and amikacin before we received the microbiology results, after which we readjusted the regimen, this time administering only tobramycin aerosol. The patient’s health gradually deteriorated; she developed bradycardia and refractory hypoxia. She died at 6 months of age, 12 days after the last isolation of D. tsuruhatensis.
We report isolation of D. tsuruhatensis in respiratory samples from a 6-month-old infant, born at 36 weeks’ gestation. Recurrent isolations of the microorganism from the same patient, including 1 time in pure culture, exclude potential contamination. In addition, clinical signs, such as pneumonia with ventilator-associated hypoxia, support infection rather than colonization. However, the patient had recurrent pneumonia, despite a successful first therapy with ceftazidime.
We also looked at the number of strains of D. tsuruhatensis isolated in our university hospitals in Marseille, France, during 2008–2015 and in the literature (Table). The microorganism has been isolated 13 times from 11 patients, including the case we describe here, mainly from blood cultures (5/11 cases) and respiratory specimens (5/11), but also from 1 urine sample. Overall, the underlying conditions were observed for 10 cases, including 2 transplant recipients. No information was available for 1 patient. Considering the presence of a vascular catheter, hospital stay longer than 48 hours, or both, all reported infections were healthcare associated. In addition, of the 6 patients in whom the bacterium had been isolated from blood cultures, all 6 had an intravascular device. These data are consistent with the 2 cases of bacteremia involving D. tsuruhatensis already reported in the literature for which intravascular device–related and underlying conditions were found (4,5). Bacterial identification systematically failed when using phenotypic methods. Since its implementation in routine laboratory tests, MALDI-TOF mass spectrometry has correctly identified D. tsuruhatensis in 4 of 8 tested isolates. For the 4 other isolates, D. tsuruhatensis was misidentified as D. acidovorans in 3 cases. Accurate identification was definitively performed using 16S rDNA sequencing.
In conclusion, D. tsuruhatensis is an opportunistic emergent healthcare-associated pathogen that can be easily misidentified. Clinicians should consider this bacterium particularly in immunocompromised patients and those with intravascular devices.
Dr. Ranc is completing his internship in hematology at Nîmes Hospital, France. His current research interest is in modeling hemostasis.


We thank Jacques Albanese and Michel Tsimaratos for their valuable help for retrieving clinical data from additional patients.
This study was supported by Méditerranée Infection and the National Research Agency under the program Investissements d’avenir, reference ANR-10-IAHU-03.


  1. Shigematsu TYumihara KUeda YNumaguchi MMorimura SKida KDelftia tsuruhatensis sp. nov., a terephthalate-assimilating bacterium isolated from activated sludge. Int J Syst Evol Microbiol2003;53:147983DOIPubMed
  2. Juárez-Jiménez BManzanera MRodelas BMartínez-Toledo MVGonzalez-López JCrognale Set al. Metabolic characterization of a strain (BM90) of Delftia tsuruhatensis showing highly diversified capacity to degrade low molecular weight phenols. Biodegradation2010;21:47589DOIPubMed
  3. Han JSun LDong XCai ZSun XYang Het al. Characterization of a novel plant growth-promoting bacteria strain Delftia tsuruhatensis HR4 both as a diazotroph and a potential biocontrol agent against various plant pathogens. Syst Appl Microbiol2005;28:6676DOIPubMed
  4. Tabak OMete BAydin SMandel NMOtlu BOzaras Ret al. Port-related Delftia tsuruhatensis bacteremia in a patient with breast cancer. New Microbiol2013;36:199201.PubMed
  5. Preiswerk BUllrich SSpeich RBloemberg GVHombach MHuman infection with Delftia tsuruhatensis isolated from a central venous catheter. J Med Microbiol2011;60:2468DOIPubMed
  6. Dubourg GAbat CRolain JMRaoult DCorrelation between sputum and bronchoalveolar lavage fluid cultures. J Clin Microbiol2015;53:9946DOIPubMed
  7. Seng PDrancourt MGouriet FLa Scola BFournier PERolain JMet al. Ongoing revolution in bacteriology: routine identification of bacteria by matrix-assisted laser desorption ionization time-of-flight mass spectrometry. Clin Infect Dis2009;49:54351DOIPubMed
  8. Drancourt MBerger PRaoult DSystematic 16S rRNA gene sequencing of atypical clinical isolates identified 27 new bacterial species associated with humans. J Clin Microbiol2004;42:2197202DOIPubMed
  9. European Committee on Antimicrobial Susceptibility Testing. Clinical breakpoints: breakpoint tables for bacteria [cited 2016 Jun 6].


Cite This Article

DOI: 10.3201/eid2403.160939
1These authors contributed equally to this article.

No hay comentarios:

Publicar un comentario